We’re managing our operating expense, managing our CapEx. Our R&D team has made great progress. We’re going to have some great things to reveal next year on the software side. Employee in turnover is about as low as we’ve ever had in the company and morale is really high. So we’re going to grow in 2024. We’ll put guidance out probably before the end of the year. We haven’t decided on exactly when, but we’ve been talking about that internally. A lot of good things going on. I mean our sales results are significantly ahead of our internal plan and where they were at this time last year. Our team already this year sold 26 multiyear engagements that had a total booking value of about $15 million. We’ve got 4 of those reps over $2.5 million in sales alone this year.
And last year, we had none. And our average deal size this year has doubled over 2022. It’s tripled over 2021, and we’ve sold over 15,000 Gene pages this year, and our target this year is 20,000, and we’re going to do even more next year. So we’re on a growth posture right now, but it’s going to be disciplined from the standpoint that we still focus on free cash flow and returning capital to shareholders. That’s still our #1 goal. We expect that the industry is still going to be somewhat challenged in terms of health care and spending in their internal resources. What we do for our customers is almost like a utility. We’re making, I think, responsible improvements to that with our investment back into our platform. I think we got a really good business model here right now, might not grow like a rocket like some people do.
But you know what, you’re getting paid along the way. And so we’ll grow next year. We’ll get some guidance out to you guys as soon as we can. We let the dust settle and do some more modeling. And hopefully, we’ll have some news for you before the end of the year on what we expect for next year. But the answer is it’s going to grow.
Eric Martinuzzi: Good luck in Q4.
Operator: [Operator Instructions]. Our next question comes from Christopher Irons.
Christopher Irons: Fantastic quarter. Thank you very much for everything. I just wanted to touch on a couple of things that you said last quarter. And Steve, if you can update last quarter, you had talked about receiving interest outside interest in the company, kind of unsolicited interest. Wondering if there’s anything new in that. In that regard, you had also talked about potentially raising the dividend at some point. I know I don’t want to get ahead of anything and certainly don’t want to line it because it was a great quarter, but I just wanted to see if you can offer an update on those 2 things.
Vincent Kelly: Yes. Let me take the second one first. The first goal was to grow into the existing dividend. At the beginning of the year, we were talking about covering 80% of our dividend with free cash — with our adjusted EBITDA less CapEx. And so we’re obviously beating that significantly. I think we’ll cover about what is 95%, Calvin this year of adjusted EBITDA less CapEx. So we’re not going to be burning through a lot of cash obviously in 2024. So we’re getting very, very close to that. We want to get above 100% before we determine what we want to do with that. And frankly, I think we have time to make that decision. So I would say for 2024, $1.25 is probably what you should bank on. And I would say for 2025, if we were going to make a change, that’s where we would be looking.
